Details
- ●Modalities: antibodies, biologics
- ●Therapeutic areas: oncology, immunology
- ●Key targets:
- ●Indications: Undisclosed
- ●Funding: Undisclosed
Partners & investors
Almirall· Investor
AstraZeneca· Investor
Key considerations
- ●AI tools in use: Absci Platform, IgDesign
- ●IPO 2021 (Nasdaq:ABSI)
- ●IgDesign publication 2024
- ●Multiple biobuck deals including AstraZeneca and Almirall
Get live updates on Absci Corporation’s hiring, filings, and partnerships. Follow in BT Pro → Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)